Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to $34.9 million.

  • Ascendis Pharma A's Share-based Compensation rose 2445.59% to $34.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $131.6 million, marking a year-over-year increase of 2728.36%. This contributed to the annual value of $131.3 million for FY2025, which is 2863.06% up from last year.
  • Per Ascendis Pharma A's latest filing, its Share-based Compensation stood at $34.9 million for Q4 2025, which was up 2445.59% from $35.8 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Share-based Compensation high stood at $35.8 million for Q3 2025, and its period low was $13.6 million during Q3 2022.
  • Over the past 5 years, Ascendis Pharma A's median Share-based Compensation value was $20.7 million (recorded in 2021), while the average stood at $22.7 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Share-based Compensation surged by 6866.91% in 2021, and later tumbled by 3444.29% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Share-based Compensation stood at $16.2 million in 2021, then decreased by 12.54% to $14.2 million in 2022, then grew by 20.93% to $17.1 million in 2023, then soared by 63.7% to $28.0 million in 2024, then rose by 24.46% to $34.9 million in 2025.
  • Its Share-based Compensation was $34.9 million in Q4 2025, compared to $35.8 million in Q3 2025 and $34.0 million in Q2 2025.